

# Society of Toxicology

## Abstract Submission Guidelines and Instructions

Abstract Submission Guidelines and Instructions **MUST BE FOLLOWED** in order for the abstract to be considered by the Program Committee. **Abstracts not conforming to the criteria described below may be subject to rejection.** The SOT Headquarters office will not be held responsible for any errors in your submission. **Please submit your abstract only one time: on-line acceptance of the abstract by the Committee obligates the author to present the paper - please review page 3.**

### Submission Dates and Instructions:

- The Program Committee requires electronic submission of the 2007 Abstracts. Deadline for submission is October 3, 2006. Fee for submission is \$40.00. The system is designed for those who will be paying their abstract fee by credit card and who have access to the internet. Submission can be entered until 11:59 PM (Eastern Time) on October 3, 2006. Access to the Abstract site can be achieved through the SOT home page ([www.toxicology.org](http://www.toxicology.org)). Simply go to the home page and select the 46th Annual Meeting menu option. Click on the Abstract Submission link and you will be directed to the on-line system. Just follow the screen prompts and in minutes, your submission will be complete.
- For on-line submissions, please follow the instructions listed on the Web site. A confirmation/receipt page is provided on-line — please print for your records.
- Written notification of withdrawal of an abstract must be received at SOT Headquarters by **October 10, 2006**, prior to review by the Program Committee. Abstracts may not be changed or withdrawn once accepted by the Program Committee. If circumstances prevent attendance, the author must arrange for the paper to be given by a substitute.  
**Acceptance of the abstract by the Committee obligates the author to present the paper and pay the meeting registration fee.**
- A "receipt of abstract" notice will be sent via e-mail to the contact author once the abstract has been processed.
- You will receive your acceptance letter and session instructions in late-November. The complexity of the program planning process prevents any changes in type of session, time or location of presentation. There are no exceptions. PowerPoint presentations that are PC compatible are required for platform presentations. Zip and CD drives will be available.

### Authorship/Sponsorship Guidelines:

- Authors are permitted as first author on only one abstract for the meeting, although there is no restriction of the number of co-authorships or sponsorships. The SOT Program Committee reserves the right to require consolidation of multiple abstracts submitted from a single study. Each abstract selected for the program must be presented by the first author.

- Abstracts submitted by **non-members** must be sponsored by a full or associate SOT member. By sponsoring the abstract, the sponsor acknowledges that the research has been done according to the SOT Code of Ethics.
- SOT members may sponsor an unlimited number of abstracts.

### Content Rules and Guidelines:

The Program Committee reviews each abstract that is submitted. The scientific quality of the abstracts presented contributes substantially towards making the SOT Annual Meeting the leading international forum for new toxicologic research. As such, there is a minimum standard for abstract acceptance. While rejection is always unfortunate, abstracts are archived material that are often cited as publications and the quality of the science presented at the Annual Meeting is paramount. The following guidelines apply:

- The abstract cannot be more than 2,300 total characters. This includes the title, body, author last name, institutions and spaces.
- The abstract may not contain tables, figures or chemical structures.
- **Abstracts describing the results of experimental studies must answer two questions: "What was done?" and "What was found?"** Abstracts **must** contain the following:
  - a statement of the rationale and scope of the study presented;
  - a brief description of the experimental procedures;
  - the data that resulted from the study; and
  - principal conclusion(s) based on interpretation of the results.
- Test compounds utilized in the study should be identified in the abstract. In cases where the length of the proper chemical name precludes its use, a manufacturer's identification number, etc., may be acceptable, provided the structure and chemical identity of the compound is included in the presentation. Abstracts will not be accepted if the authors are unable to disclose the chemical identity of the compound(s) used in the study.

# Abstract Submission Guidelines and Instructions

*(continued)*

- Phrases such as "results/data will be discussed" convey no information as to the outcome of the studies and are unacceptable. In the case of studies that do not describe laboratory or field experiments, all the guidelines above apply with the following modifications:
  - instead of experimental procedures, the research or assessment approach should be briefly described, and
  - instead of resultant data, the study's results or findings should be summarized explicitly
- Abstracts describing new initiatives or science policy in the regulatory community must clearly describe the impact on practice of toxicology and/or risk assessment. Literature surveys or reviews and background materials are insufficient in and of themselves.
  - Define all non-standard acronyms.
  - All animal experimentation must be carried out in accordance with the Society's criteria for the care and use of animals in research.
  - All abstracts submitted with human testing require that IRB protocol has been followed and approval obtained.
  - All abstracts submitted will accept assigned time slot.
  - All presenters are responsible for registering for the Annual Meeting and paying the registration fee.

## Category List

The categories listed below are used to group abstracts on similar subjects for the program Committee review and session programming.

Alternatives to Mammalian Models	Epidemiology/Exposure Assessment	Neurotoxicity, Pesticide
Apoptosis	Food Safety/Nutrition	Oxidative Injury
Bioinformatics	Gene Regulation	Persistent Organic Chemicals (POPs)
Biological Modeling	Genetic Polymorphisms	Pesticides
Biomarkers/Biomonitoring	Genotoxicity/DNA Repair	Pharmaceuticals
Biotransformation/Cytochrome P450	Hypersensitivity	Receptors
Carcinogenesis	Immunotoxicity	Regulatory/Policy
Cardiovascular System	Inhalants & Cardiopulmonary	Reproductive System
Chemical & Biological Weapons	Kidney	Risk Assessment
Children's Health/Juvenile Toxicity	Liver	Safety Assessment 'Non-Pharmaceutical'
Developmental/Teratology	Metals	Safety Evaluation
Disposition/Pharmacokinetics	Natural Products	Signal Transduction
Ecotoxicology	Nervous System	Skin
Endocrine	Neurotoxicity, Developmental	
	Neurotoxicity, Metals	